Stability, speed and strategy: Inside Australia’s early‑stage edge

In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role. Host   / jennifersmithparker  , Director of Insights, BioSpace Guests   / jerome-barley  , Commercial Director, Avion Medical   / ryanrklein  , Vice President, Business Development, US and APAC, Resolian Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.